MDxHealth Is Continually Improving Their Subscribers Experience

MDxHealth Is Continually Improving Their Subscribers Experience 
LIEGE, BELGIUM -- (Marketwire) -- 10/29/12 --  In order to continue
receiving MDxHealth's press releases or other Company information,
please click on the link below to select the type and language of the
press releases offered. then press the 'subscribe' link at the top right of
the page.  
We thank you in advance for the interest shown towards our Company. 
About MDxHealth  
BRUSSELS: MDXH) is a molecular diagnostics company based in Irvine,
CA and Liege Belgium and that develops and commercializes advanced
epigenetic tests for cancer assessment and the personalized treatment
of patients. By applying patented DNA methylation platform and
biomarkers, MDxHealth helps to address a large and growing unmet
medical need for better cancer diagnosis and treatment information.
For more information visit 
This press release contains forward-looking statements and estimates
with respect to the anticipated future performance of MDxHealth and
the market in which it operates. Such statements and estimates are
based on assumptions and assessments of known and unknown risks,
uncertainties and other factors, which were deemed reasonable but may
not prove to be correct. Actual events are difficult to predict, may
depend upon factors that are beyond the company's control, and may
turn out to be materially different. MDxHealth expressly disclaims
any obligation to update any such forward-looking statements in this
release to reflect any change in its expectations with regard thereto
or any change in events, conditions or circumstances on which any
such statement is based unless required by law or regulation. 
For more information:  
Dr. Jan Groen 
US: +1 949 812 6979
BE: +32 4 364 20 70 
Mike Sinclair
Halsin Partners
UK: +44 20 7318 2955
Cell: +44 7968 022075 
Press spacebar to pause and continue. Press esc to stop.